The expansion arrives as healthcare systems prioritize supply chain resilience and the diversification of biologic medicine sources. By bolstering its industrial platform, the firm aims to ensure the continuity of treatment for patients managing rare and chronic conditions. This infrastructure investment allows Biosidus to engage with health authorities and potential partners seeking reliable access to high-quality therapeutic alternatives.
In section Releases
Biosidus Scales Up Biologics Output to Meet Global Demand
Buenos Aires-based Biosidus has brought a new bioreactor plant online, marking a significant push to increase the production of agalsidase beta. This move expands the company’s manufacturing footprint as it looks to provide sustainable sources of enzyme replacement therapy for patients suffering from Fabry disease on an international scale.
Following the domestic launch of its agalsidase beta therapy in 2025, the company is now positioning its program for cross-border distribution. Mario Koch, Director of Rare Diseases, emphasized that the added capacity serves the company’s broader objective of making complex biologics more accessible globally. Biosidus is currently prepared to evaluate supply requirements in markets where regulatory pathways support the introduction of new biosimilar options.
Comments (0)
No comments yet. Be the first!